Samsung Announces New NAND Flash Facility to Address Future Data Center and Mobile Demands
Located inside Pyeongtaek's Line 2 in Korea, the new facility is slated for mass production…
6 years ago
Wire Stories
Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time
Pre-clinical data for Celltrion’s antiviral antibody treatment candidate demonstrate a 100-fold reduction in viral load…
6 years ago
YouTube Entrepreneur Matt Par to Host a Free Training Webinar That Will Help Millennials Monetize Their Channels
SAN FRANCISCO--(BUSINESS WIRE)--19-year-old YouTube expert Matt Par has created a free training webinar for wannabe…
6 years ago
Global Leading Institutions Took Stakes in Yeahka, Showing Confidence in Its Long-Term Prospects
HONG KONG--(BUSINESS WIRE)--YEAHKA LIMITED, China’s leading payment and business service technology platform commences trading on…
6 years ago
ViaBTC Group Announces Strategic Upgrade to Advance Innovation and Improve Customer Experience
HONG KONG--(BUSINESS WIRE)--ViaBTC Group, an innovative technology company specialized in blockchain and dedicated to providing…
6 years ago
Crash Barrier Systems Market 2020-2024 | Implementation of Road Safety Programs to Boost Market Growth | Technavio
LONDON--(BUSINESS WIRE)--#CrashBarrierSystemsMarket--The crash barrier systems market is expected to grow by USD 1.29 billion during…
6 years ago
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial
61.9% of patients with HER2 mutant metastatic non-small cell lung cancer treated with ENHERTU achieved…
6 years ago
ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial
TOKYO & BASKING RIDGE, N.J. & MUNICH--(BUSINESS WIRE)--Results from the phase 2 DESTINY-CRC01 trial of…
6 years ago
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks
Validation of Type II Variation will allow Takeda to commence launches in Europe later this…
6 years ago
Alteogen Presents the First-in-Human Data on ALT-P7, a HER2-targeting Antibody-Drug Conjugate (ADC) at ASCO 2020
DAEJEON, South Korea--(BUSINESS WIRE)--#ALTB4--Alteogen Inc. (KOSDAQ:196170) has today presented at ASCO results from the First-in-Human…
6 years ago